[Dyspnea and quality of life in chronic obstructive pulmonary disease].
Sanjuás
C
C
Servei de Pneumologia. Hospital del Mar. Barcelona. Spain. Csanjuas@imas.imim.es
D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004417:Dyspnea / Q000209:etiology*; D004644:Emotions; D015444:Exercise; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006304:Health Status; D006801:Humans; D007407:Interviews as Topic; D009241:Ipratropium / Q000008:administration & dosage / Q000627:therapeutic use; D015999:Multivariate Analysis; D010919:Placebos; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology / Q000534:rehabilitation; D011788:Quality of Life; D000068299:Salmeterol Xinafoate; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D013997:Time Factors; D000069447:Tiotropium Bromide
D001993:Bronchodilator Agents; D010919:Placebos; D012602:Scopolamine Derivatives; D000068299:Salmeterol Xinafoate; D009241:Ipratropium; D000420:Albuterol; D000069447:Tiotropium Bromide